4 results
The objective of the study is to determine the effectivity of this consolidation treatment, as well as the conversion rate of PR to CR in patients in PR before consolidation and the effect on the immunological recovery.
To determine the conversion rate of PR to CR (i.e. PET negativity) after a single dose of 90Y-ibritumomab tiuxetan (a dose of 14.8 MBq/kg or 0.4 mCi/kg, max 1184 MBq or 32mCi) in patients with grade 1-3a, stage II, III or IV follicular lymphoma with…
To evaluate the efficacy and safety of Zevalin compared with observation alone in patients who are in PET-negative complete remission (CR) after first-line R-CHOP or R-CHOP like therapy.
The objective of this project is to assess the applicability of [18F]PK209 for in vivo imaging of the NMDA receptor.